RemeGen Co.Ltd.
Albumin-bound Paclitaxone(RemeGen Co., Ltd.)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: Targeting the vitamin D receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose.
Breast Cancer
Breast Cancer
Recruiting
Govitecan in Untreated, Advanced Triple-Negative
lipid nanoparticles, nanostructured lipid carriers, polymeric, micelles, dendrimers), inorganic (c
novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose
Targeting the vitamin D receptor
apoptosis via upregulated Bax and Caspase-3 levels
biomarker analysis
resistance to oxaliplatin, fluorouracil, and albumin-bound paclitaxel
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
RemeGen Co.Ltd.
Albumin-bound Paclitaxone(RemeGen Co., Ltd.)은 Breast Cancer 표적 ADC로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: Targeting the vitamin D receptor. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose.
Breast Cancer
Breast Cancer
Recruiting
Govitecan in Untreated, Advanced Triple-Negative
lipid nanoparticles, nanostructured lipid carriers, polymeric, micelles, dendrimers), inorganic (c
novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose
Targeting the vitamin D receptor
apoptosis via upregulated Bax and Caspase-3 levels
biomarker analysis
resistance to oxaliplatin, fluorouracil, and albumin-bound paclitaxel
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.